On March 30, 2021 Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, reported a collaboration with Asher Biotherapeutics for systems pharmacology modeling in solid tumors (Press release, Applied BioMath, MAR 30, 2021, View Source [SID1234577390]). "We have experience that development of a biotherapeutic has the best chance of success when the R&D process is supported by mathematical modeling," said Lioudmila Tchistiakova, Entrepreneur in Residence at Third Rock Ventures. "We have chosen to collaborate with Applied BioMath given their proven track record in this space," said Ivana Djuretic, PhD, Chief Scientific Officer of Asher Biotherapeutics. "This collaboration will enable us to confidently predict pharmacokinetics, receptor occupancy, and pharmacodynamics of our lead molecule."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis. "Systems pharmacology modeling’s impact is extremely effective when leveraged early on in the R&D process," said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "Incorporating modeling early on helps the project team gain thorough understanding of their lead molecule which in turn helps increase the likelihood of success in the clinic."